Jarrod Adkison, MD
Radiation Oncology · Dothan, ALNPI 1790719318
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,278, 5.7 times the $223 reported in 2019.
Across 135 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$616
- Merck$356
- Novartis$236
- AstraZeneca$196
- Johnson & Johnson$186
- Siemens Medical Solutions USA, Inc.$174
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,31199%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 29 | $616 |
| Merck | 16 | $356 |
| Novartis | 11 | $236 |
| AstraZeneca(2 entities) | 5 | $196 |
| Johnson & Johnson | 5 | $186 |
| Siemens Medical Solutions USA, Inc. | 1 | $174 |
| Sanofi | 4 | $122 |
| E.r. Squibb & Sons, L.L.C. | 6 | $122 |
| EMD Serono, Inc. | 4 | $108 |
| Intuitive Surgical | 1 | $106 |
| Amgen | 6 | $101 |
| Lilly USA, LLC | 5 | $94 |
| Regeneron Healthcare Solutions, Inc. | 3 | $84 |
| Incyte Corporation | 4 | $83 |
| Novocure Inc. | 3 | $77 |
| Eisai Inc. | 3 | $67 |
| Kyowa Kirin, Inc. | 2 | $58 |
| Blue Earth Diagnostics | 2 | $51 |
| Beone Medicines USA, Inc. | 2 | $48 |
| Apellis Pharmaceuticals, Inc. | 2 | $46 |
| AbbVie | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Exelixis Inc. | 2 | $40 |
| Stemline Therapeutics Inc. | 2 | $37 |
| Genmab U.S., Inc. | 2 | $37 |
| Myovant Sciences Inc. | 2 | $36 |
| Pfizer | 2 | $35 |
| Coherus Oncology, Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $21 |
| Dendreon Pharmaceuticals LLC | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$125
- ORGOVYX$115
- Erleada$113
- Da Vinci Surgical System$106
How this compares
$3,350 in reported general payments places this provider in the 75th percentile of 87 radiation oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 65 | $173,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $14,042 |
| Tamsulosin Hcl | 248 | $4,387 |
| Ondansetron Hcl | 137 | $3,470 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 132 | $2,915 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 46 | $1,645 |
| Ondansetron OdtOndansetron | 43 | $1,613 |
| SsdSilver Sulfadiazine | 43 | $1,483 |
| Lidocaine Hcl ViscousLidocaine Hcl | 64 | $1,445 |
| Prochlorperazine Maleate | 36 | $1,416 |
| Triamcinolone Acetonide | 91 | $1,391 |
| Dexamethasone | 34 | $1,340 |
| Sucralfate | 38 | $1,311 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 13 | $1,032 |
| Megestrol Acetate | 14 | $1,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $616 | $173,74865 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 87 radiation oncology providers in Alabama.
Other radiation oncology in Dothan
- Kenyon MeadowsDothan$993
- Alexander WhitleyMontgomery$441K
- Drexell BoggsBirmingham$35K
- Christopher JahrausAlabaster$28K
- Christopher WilleyBirmingham$13K
- Adam KoleBirmingham$11K
- William HixsonFairhope$10K
- John GleasonHuntsville$9K
- Andrew McDonaldBirmingham$8K
- Hoyt ChildsHuntsville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.